Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF)

International Journal of Cancer

Volumn 122, Issue 2, 2008, Pages 461-467

  Yamamoto, Nobuto ^a   Suyama, Hirofumi ^b   Yamamoto, Nobuyuki ^a   Ushijima, Naofumi ^a  

^a Socrates Institute for Therapeutic Immunology   (United States)

^b Nagasaki Immunotherapy Research Group   (Japan)

Author keywords

N acetylgalactosaminidase; Deglycosylation; Immunotherapy; Macrophage activating factor; Tumoricidal

Indexed keywords

ALPHA N ACETYLGALACTOSAMINIDASE; MACROPHAGE ACTIVATING FACTOR; VITAMIN D BINDING PROTEIN; VITAMIN D DERIVATIVE;

ANEMIA; ARTICLE; BREAST ADENOCARCINOMA; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CELL MEMBRANE; CLINICAL ARTICLE; CONTROL GROUP; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; HUMAN; HUMAN TISSUE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME;

ADULT; AGED; ALPHA-N-ACETYLGALACTOSAMINIDASE; BREAST NEOPLASMS; FEMALE; GLYCOSYLATION; HUMANS; IMMUNOTHERAPY; MACROPHAGE ACTIVATION; MACROPHAGE-ACTIVATING FACTORS; MACROPHAGES; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; TETRADECANOYLPHORBOL ACETATE; VITAMIN D-BINDING PROTEIN;

EID: 36849085584     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23107     Document Type: Article

References (57)

1. Silliman RA, Balducci L, Goodwin JS, Holmes FF, Leventhal EA. Breast cancer care in old age: what we know, don't know and do. J Natl Cancer Inst 1993;85:190-99.
2. Boring CC, Squires TS, Tong T. Cancer statistics, 1993. CA Cancer J Clin 1993;43:7-26.
3. Yancik R, Ries LG, Yates JW. Breast cancer in aging women: a population-based study of contrasts in stage, surgery and survival. Cancer 1989;63:976-81.
4. Holland R, Verbeek ALM. Prognostic assessment in node-negative breast cancer patients. J Clin Oncol 1990;8:1451-3.
5. Spielmann M, Dorval T, Turpin F, Antoine E, Jouve M, Maylevin F, Lacombe D, Rouesse J, Pouillart P, Tursz T, Merle S. Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer. J Clin Oncol 1994;12:1764-70.
6. Morton D, Eibler FR, Malmgren RA, Wood WC. Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery 1970;68:158-64.
7. Zbar B, Tanaka T. Immunotherapy of cancer: regression of tumors after intralesional injection of living Mycobacterium bovis. Science 1971;172:271-3.
8. Ngwenya BZ, Yamamoto N. Activation of peritoneal macrophages by lysophosphatidylcholine. Biochim Biophys Acta 1985;839:9-15.
9. Ngwenya BZ, Yamamoto N. Effects of inflammation products on immune systems: lysophosphatidylcholine stimulates macrophages. Cancer Immunol Immunother 1986;21:174-82.
10. Ngwenya BZ, Yamamoto N. Contribution of lysophosphatidylcholine treated nonadherent cells to mechanism of macrophage activation. Proc Soc Exp Biol Med 1990;193:118-24.
11. Yamamoto N, Ngwenya BZ. Activation of macrophages by lysophospholipids, and ether derivatives of neutral lipids and phospholipids. Cancer Res 1987;47:2008-13.
12. Yamamoto N, Ngwenya BZ, Sery TW, Pieringer PA. Activation of macrophages by ether analogues of lysophospholipids. Cancer Immuno Immunother 1987;25:185-92.
13. Yamamoto N, St. Claire DA, Homma S, Ngwenya BZ. Activation of mouse macrophages by alkylglycerols, inflammation products of cancerous tissues. Cancer Res 1988;48:6044-9.
14. Homma S, Yamamoto N. Activation process of macrophages after in vitro treatment of mouse lymphocytes with dodecylglycerol. Clin Exp Immunol 1990;79:307-13.
15. Yamamoto N, Hoober JK, Yamamoto S, Yamamoto N. Tumoricidal capacities of macrophages photodynamically activated with hematoporphyrin derivative. Photochem Photobiol 1992;56:245-50.
16. Fidler JJ, Schroit AJ. Recognition and destruction of neoplastic cells by activated macrophages: discrimination of altered self. Biochim Biophys Acta 1988;948:151-73.
17. Keller R. The macrophage response to infectious agents: mechanisms of macrophage activation and tumour cell killing. Res Immunol 1993;144:271-3.
18. Klostergaard J. Macrophage tumoricidal mechanisms. Res Immunol 1993;144:274-6.
19. Yamamoto N, Homma S, Millman I. Identification of the serum factor required for in vitro activation of macrophages: role of vitamin D binding protein (group-specific component, Gc) in lysophospholipid activation of mouse peritoneal macrophases. J Immunol 1991;147: 273-80.
20. 3 binding protein required for in vitro activation of macrophages after dodecylglycerol treatment of mouse peritoneal cells. Immunology 1991;74:420-4.
21. Homma S, Yamamoto M, Yamamoto N. Vitamin D binding protein (group-specific component, Gc) is the sole serum protein required for macrophage activation after treatment of peritoneal cells with lysophosphatidylcholine. Immunol Cell Biol 1993;71:249-57.
22. 3 binding protein (group-specific component, Gc) is a precursor for the macrophage activating signal from lysophosphatidylcholine-treated lymphocytes. Proc Natl Acad Sci USA 1991;88:8539-43.
23. 3 binding protein (Group-specific component) to a macrophage activating factor by the stepwise action of β-galactosidase of B cells and sialidase of T cells. J Immunol 1993;151:2794-2802.
24. Naraparaju VR, Yamamoto N. Roles of β-galactosidase of B lymphocytes and sialidase of T lymphocytes in inflammation-primed activation of macrophages. Immunol Lett 1994;43:143-8.
25. 3 binding protein with adjuvant activity for antibody production. Mol Immunol 1996;33:1157-64.
26. Yamamoto N. Vitamin D and the immune system. In: Delves PJ, Roitt 1, eds. Encyclopedia of immunology, 2nd edn. London: Academic Press, 1998. 2494-9.
27. Yamamoto N. In vitro enzymatic conversion of glycosylated human vitamin D binding protein to a potent macrophage activating factor. U.S. Patent No. 5,177,002. 1993.
28. Yamamoto N, Naraparaju VR, Asbell SO. Deglycosylation of serum vitamin D-binding protein and immunosuppression in cancer patients. Cancer Res 1996;56:2827-31.
29. Yamamoto N, Naraparaju VR, Urade M. Prognostic utility of serum α-N-acetylgalactosaminidase and immunosuppression resulted from deglycosylation of serum Gc protein in oral cancer patients. Cancer Res 1997;57:295-9.
30. Yamamoto N. Diagnostic and prognostic ELISA assays of serum or plasma α-N-acctylsalactosaminidase for cancer. U.S. Patent No. 5,712,104. 1998.
31. Yamamoto N. Diagnostic and prognostic indices for cancer and AIDS. U.S. Patent No. 5,620,846. 1997.
32. 3-binding protein-derived macrophage activating factor on Ehrlich tumor bearing mice. Proc Soc Exp Biol Med 1999;220:20-26.
33. Yamamoto N, Ueda M. Eradication of HIV by treatment of HIV-infected/AIDS patients with vitamin D-binding protein (Gc protein)-derived macrophage activating factor (GcMAF). Proc Int Cong Imm 2004;197-200.
34. 3-binding protein and immunosuppression in HIV-infected patients. AIDS Res Hum Retroviruses 1995;11:1373-8.
35. Yamamoto N. Pathogenic significance of α-N- acetylgalactosaminidase found in the envelope glycoprotein gp160 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2006;22:262-71.
36. Yamamoto N, Urade M. Pathogenic significance of α-N- acetylgalactosaminidase found in the hemagglutinin of influenza virus. Microbes Infect 2005;7:674-81.
37. Yamamoto N, Naraparaju VR. Immunotherapy of BALB/c mice bearing Ehrlich ascites tumor with vitamin D-binding protein-derived macrophage activating factor. Cancer Res 1997;57:2187-92.
38. Yamamoto N, Urade M, Ueda M. Potent tumoricidal capacity of macrophages activated by Gc protein-derived macrophage activating factor (GcMAF) and its therapeutic efficacy for prostate, breast and colorectal cancers. J Immunother 2005;28:642.
39. Yamamoto N. Preparation of potent macrophage activating factors derived from cloned vitamin D binding protein and its domain and their therapeutic usage for cancer, HIV-infection and osteopetrosis. U.S. Patent No. 6,410,269. 2002.
40. Yamamoto N, Ueda M. Therapeutic efficacy of vitamin D-binding protein (Gc protein)-derived macrophage activating factor (GcMAF) for prostate and breast cancers. Immunology 2004 (Medmond):201-4.
41. Zhang S, Cordon-Cardo C, Zhang HS, Reuter VE, Adluri S, Hamilton WB, Lloyd KO, Livingston PO. Selection of tumor antigens as targets for immune attack using immunohistochemistry. I. Focus on gangliosides. Int J Cancer 1997;73:42-9.
42. Zhang S, Zhang HS, Cordon-Cardo C, Reuter VE, Singhal AK, Lloyd KO, Livingston PO. Selection of tumor antigens as targets for immune attack using immunohistochemistry. II. Blood group-related antigens. Int J Cancer 1997;73:50-6.
43. Zhang S, Zhang HS, Cordon-Cardo C, Ragupathi G, Livingston PO. Selection of tumor antigens as targets for immune attack using immunohistochemistry. III. Protein antigen. Clin Cancer Res 1998;4:2669-76.
44. Musselli C, Ragupathi G, Gilewski T, Panageas KS, Spinat Y, Livingston PO. Reevaluation of the cellular immune response in breast cancer patients vaccinated with MUC1. Int J Cancer 2002;97:660-7.
45. Tondini C, Hayes DF, Gelman R, Henderson IC, Kufe DW. Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Cancer Res 1988;48:4107-112.
46. Gion M, Mione R, Leon AE, Dittadi R. Comparison of the diagnostic accuracy of CA27.29 and CA15.3 in primary breast cancer. Clin Chem 1999;45:630-7.
47. Korbelik M, Naraparaju VR, Yamamoto N. Value of serum α-N-acetylgalactosaminidase measurement for the assessment of tumor response to radio- and photodynamic therapy. Br J Cancer 1998;77:1009-14.
48. 3- sepharose chromatography. Anal Biochem 1986;157:262-9.
49. Yamamoto N, Willett NP, Lindsay DD. Participation of serum proteins in the inflammation-primed activation of macrophages. Inflammation 1994;18:311-22.
50. 3-binding protein and albumin. Infect Immun 1993;61:5388-91.
51. 3-binding protein has a potent adjuvant activity for immunization. Immunol Cell Biol 1998;76:237-44.
52. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
53. Lichenstein HS, Lyons DE, Wurfels MM, Johnson DA, McGinley MD, Leidli JC, Trollinger DB, Mayer JP, Wright SD, Zukowski MM. Afamin is a new member of the albumin, α-fetoprotein and vitamin D-binding protein gene family. J Biol Chem 1994;269:18149-54.
54. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Night SC, Carbone DP, Gabrilovich DI. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2001;166:678-89.
55. Platt N, Gordon S. Is the class A macrophage scavenger receptor (SR-A) multifunctional? - the mouse's tale. J Clin Invest 2001;108:649-54.
56. Taylor PR, Martinez-Pomares L, Stacey M, Lin H-H, Brown GD, Gordon S. Macrophage receptors and immune recognition. Annu Rev Immunol 2005;23:901-44.
57. Yamamoto N, Ueda M. Treatment of cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF) rapidly eradicates cancerous cells. J Immunother 2006;29:677-8.